Journal of Pharmacology and Pharmacotherapeutics

MOLECULES OF THE MILLENNIUM
Year
: 2014  |  Volume : 5  |  Issue : 2  |  Page : 175--178

Lorcaserin: A novel antiobesity drug


Dick B. S. Brashier, AK Sharma, Navdeep Dahiya, SK Singh, Anjan Khadka 
 Department of Pharmacology, Armed Forces Medical College, Pune, Maharashtra, India

Correspondence Address:
Dick B. S. Brashier
Department of Pharmacology, Armed Forces Medical College, Pune 411 040, Maharashtra
India

Obesity is a major co-morbidity with hypertension and diabetes mellitus. There are few drugs for treatment of obesity like orlistat and recentlty approved drug lorcaserin. Lorcaserin has serotonergic properties and acts as an anorectic. It may cause serious side effects, including serotonin syndrome, particularly when taken with certain medicines that increase serotonin levels or activate serotonin receptors. Although, mainstay and first line of approach of treatment will always remain in having low calorie diet and increase in physical activity. Lorcaserin has come as a new hope to achieve success in treating obese patients but still a long road with further extensive research to be undertaken in the treatment of obesity.


How to cite this article:
Brashier DB, Sharma A K, Dahiya N, Singh S K, Khadka A. Lorcaserin: A novel antiobesity drug.J Pharmacol Pharmacother 2014;5:175-178


How to cite this URL:
Brashier DB, Sharma A K, Dahiya N, Singh S K, Khadka A. Lorcaserin: A novel antiobesity drug. J Pharmacol Pharmacother [serial online] 2014 [cited 2019 Dec 16 ];5:175-178
Available from: http://www.jpharmacol.com/article.asp?issn=0976-500X;year=2014;volume=5;issue=2;spage=175;epage=178;aulast=Brashier;type=0